home / stock / cere / cere news


CERE News and Press, Ceres Inc. From 11/01/23

Stock Information

Company Name: Ceres Inc.
Stock Symbol: CERE
Market: NASDAQ
Website: cerevel.com

Menu

CERE CERE Quote CERE Short CERE News CERE Articles CERE Message Board
Get CERE Alerts

News, Short Squeeze, Breakout and More Instantly...

CERE - Expected US Company Earnings on Wednesday, November 1st, 2023

Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...

CERE - Cerevel Therapeutics GAAP EPS of -$0.61 beats by $0.04

2023-11-01 06:31:38 ET More on Cerevel Therapeutics Cerevel: Drop On Data Delay For EMPOWER Program Provides Buy Opportunity Cerevel Therapeutics prices $450M stock Cerevel downgraded at Bank of America on delayed readouts Seeking Alpha’s Quant Rating ...

CERE - Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Raised $499 million of net proceeds from public offering of common stock, expected to support operations into 2026 2024 data readout timelines for emraclidine, darigabat, and tavapadon remain on track Tavapadon investor webcast scheduled for December 11, 2023 Conference ...

CERE - Expected earnings - Cerevel Therapeutics Holdings Inc.

Cerevel Therapeutics Holdings Inc. (CERE) is expected to report $-0.63 for Q3 2023

CERE - Cerevel Therapeutics says Perceptive Advisors buys 876.8K shares

2023-10-18 07:07:15 ET More on Cerevel Therapeutics Cerevel: Drop On Data Delay For EMPOWER Program Provides Buy Opportunity Cerevel Therapeutics prices $450M stock For further details see: Cerevel Therapeutics says Perceptive Advisors buys 876.8K shares

CERE - Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2023 financial results and business updates on Wedn...

CERE - Cerevel Therapeutics prices $450M stock

2023-10-12 05:30:22 ET More on Cerevel Therapeutics Cerevel: Drop On Data Delay For EMPOWER Program Provides Buy Opportunity Cerevel downgraded at Bank of America on delayed readouts Cerevel Therapeutics falls on delayed data readouts Seeking Alpha’s Q...

CERE - Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 19,728,189 s...

CERE - Cerevel Therapeutics starts public offering of $400M of shares

2023-10-11 16:05:17 ET More on Cerevel Therapeutics Cerevel downgraded at Bank of America on delayed readouts Seeking Alpha’s Quant Rating on Cerevel Therapeutics Cerevel Therapeutics falls on delayed data readouts For further details see: Cerevel ...

CERE - Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the Morgan Stanley 21st Annual Global Healt...

Previous 10 Next 10